3 Japanese Dividend Stocks With 5% Yields Income Investors May Want To Recheck

With US composite PMI pointing to the strongest expansion since April 2022, income investors are again paying close attention to what powers their returns. Solid activity and firm hiring keep inflation and rates in focus, which leaves dependable cash dividends looking especially attractive. This article looks at three stocks from the Dividend Powerhouses screener that offer 5%+ yields with covered, growing and stable payouts.

The three stocks covered below are just a sample, since the full Dividend Powerhouses screen surfaced 461 more companies with similarly compelling income stories that are not included here. If you want to identify, filter and analyze those high-yield opportunities yourself, head straight to the Dividend Powerhouses (3%+ Yield) screener.

Canon is a diversified Japanese equipment company best known for its printers and imaging products, but it also has meaningful medical and industrial businesses. The cash-generating Office and Production Printing operations, which sell multifunction printers, laser printers and document solutions, are a key reason Canon fits the Dividend Powerhouses theme because they help fund its shareholder focused dividend policy. Canon’s current market value is about ¥3.9t, putting it firmly in large cap territory.

Income focused investors may want to look closely at Canon because its high yield is tied to businesses that generate recurring cash flow, especially in office and production printing, and recent half year results show higher sales and earnings that support that story. At the same time, the stock is flagged as trading well below an estimated fair value and carries a high quality earnings tag, which can be rare for higher yielding companies. The catch is that some analysis points to an unstable dividend track record and only modest earnings growth forecasts, so the headline yield comes with questions about how consistent those payouts will be over a full cycle.

Canon’s high yield, recurring cash flow and quality earnings tag suggest a story the market may be mispricing. Get the full context in the 4 key rewards and 1 important warning sign

Build your own dividend powerhouse shortlist

Canon and the two other stocks in this list all come from a single Simply Wall St screen, but the real value for you is in shaping your own filters. Use our flexible Screener to mix criteria like valuation, dividends, balance sheet strength and risks, or jump straight into our curated Investing Ideas for ready made starting points.

Tokio Marine Holdings is a global insurance group that sells a wide range of non-life and life policies, from personal and commercial cover to reinsurance and asset management services. Together these create the steady cash flows that link it to the Dividend Powerhouses theme. Revenue is spread across domestic property and casualty insurance of about ¥3.16t, overseas insurance of roughly ¥5.41t and domestic life insurance of around ¥445b, with additional contribution from solution and other business lines of about ¥328b. The company is a large cap with a market value of roughly ¥13.96t.

Tokio Marine may appeal to investors who want a large insurer whose core underwriting and life businesses are designed to generate dependable cash, while still reshaping itself through the Re-New efficiency drive, disaster resilience solutions and regular share buybacks. The dividend is supported by long established operations and recent results show earnings per share edging higher, but profit margins have come under pressure and last year’s earnings decline highlights that the story does not move in a straight line. There is also a sizeable gap to some value estimates, which combines with the income profile to create a balance of solid foundations and execution risk that invites closer inspection.

Tokio Marine’s earnings, buybacks and dividend yield are all pulling in the same direction, yet the share price story still feels incomplete. Get the full picture in the 3 key rewards and 1 important warning sign

Daiichi Sankyo Company is a global pharmaceutical group focused on oncology and cardiometabolic treatments, where blockbuster drugs like Enhertu and Lixiana/Savaysa help underpin its dividend paying profile through steady cash flows. The company generates about ¥2,223.2b in revenue from a single Pharmaceutical Operation segment and has a market value of roughly ¥5,158.1b, which places it among the larger players in the sector.

Daiichi Sankyo provides exposure to oncology treatments that are already on the market, with recent Enhertu and Datroway approvals and trial wins supporting cash flow that contributes to its 3.53% dividend yield. At the same time, the stock trades below some fair value estimates and carries earnings growth forecasts, which together may appeal to investors who believe current expectations are too low. The trade off is that the dividend is not fully covered by free cash flow and profits rely heavily on a handful of cancer drugs, so any setback on pricing, safety or competition could affect both earnings and those income streams.

Accelerating oncology cash flows at Daiichi Sankyo Company may be masking a deeper shift in expectations. Get the forward looking context, including growth hopes and the key swing risk, in the analyst forecasts for Daiichi Sankyo Company

Seeking Fresh Alternatives For Your Income?

Fresh ideas move first. While others react to yesterday’s headlines, you can scan curated stocks with real momentum before the crowd catches on. Act now and get in early.

• Explore potential momentum in tiny companies that already have numbers to back them up by screening 1 elite penny stocks with strong financials before they appear on everyone else’s radar.
• Identify companies powering AI behind the scenes as demand changes and use the curated 55 AI infrastructure stocks to see which stocks may be building tomorrow’s rails.
• Prepare for possible shifts in precious metals sentiment and review the hand picked 32 elite gold producer stocks while these producers may still be under the radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com